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Three-Dimensional Thoracic Radiation Followed by
Consolidative Docetaxel and Maintenance Gefitinib for
Patients with Stage III Non-small Cell Lung Cancer
Brian Center, MD, William Jeffrey Petty, MD, Diandra Ayala, BS, William H. Hinson, PhD,
James Lovato, MS, James Capellari, MD, Timothy Oaks, MD, Antonius A. Miller, MD,
and Arthur William Blackstock, MD
Background: Concurrent radiation and chemotherapy is the stan-
dard of care for good performance status patients with stage III
non-small cell lung cancer. Locoregional control remains a signifi-
cant factor relating to poor outcome. Preclinical and early clinical
data suggest that docetaxel and gefitinib have radiosensitizing ac-
tivity. This study sought to define the maximum tolerated dose of
weekly docetaxel that could be given with daily gefitinib and
concurrent thoracic radiation therapy.
Patients and Materials: Patients with histologically confirmed, inop-
erable stage III non-small cell lung cancer and good performance status
(Eastern Cooperative Oncology Group 0–1) were eligible for this study.
Patients received three-dimensional conformal thoracic radiation to a
dose of 70 Gy concurrently with oral gefitinib at a dose of 250 mg daily
and intravenous, weekly docetaxel at escalating doses from 15 to 30
mg/m2 in cohorts of patients. Patients were given a 2-week rest period
after the concurrent therapy, during which they received only gefitinib.
After the 2-week rest period, patients received consolidation chemo-
therapy with docetaxel 75 mg/m2 given every 21 days for two cycles.
Maintenance gefitinib was continued until disease progression or study
completion.
Results: Sixteen patients were enrolled on the study between De-
cember 2003 and April 2007 with the following characteristics:
median age, 64 years (range 43–79 years); M/F: 9/7; and perfor-
mance status 0/1, 1/15. Dose-limiting pulmonary toxicity and esoph-
agitis were encountered at a weekly docetaxel dose of 25 mg/m2,
resulting in a maximum tolerated dose of 20 mg/m2/wk. Overall,
grade 3/4 hematologic toxicity was observed in 27% of patients.
Grade 3/4 esophageal and pulmonary toxicities were reported in
27% and 20% of patients, respectively. The overall response rate
was 46%, and the median survival for all patients was 21 months.
Conclusions: Concurrent thoracic radiation with weekly docetaxel
and daily gefitinib is feasible but results in moderate toxicity. For
further studies, the recommended weekly docetaxel dose for this
chemoradiation regimen is 20 mg/m2.
Key Words: Chemoradiation, Lung cancer, Epidermal growth fac-
tor receptor, Pulmonary toxicity.
(J Thorac Oncol. 2010;5: 69–74)
Despite advances in chemotherapy, radiation therapy, andsurgery, the overall 5-year survival for patients with
locally advanced non-small cell lung cancer (NSCLC) re-
mains less than 15%.1 The inability to achieve locoregional
control is a significant factor in the poor outcome for these
patients. With radiation alone, more than half of patients relapse
within the chest.2 Improvements in locoregional control and
overall survival have been suggested by multiple phase II3–6 and
randomized phase III trials7–10 using combined modality ther-
apy. Based on these studies, the current standard of care in the
United States for advanced, unresectable NSCLC is concurrent
chemotherapy and thoracic radiation.11
The semisynthetic taxane, docetaxel, has been shown to
have considerable activity as a first or second-line agent in
NSCLC.12 Of particular interest for combined modality treat-
ment, docetaxel acts as a radiosensitizer through its induction
of a G2/M phase cell cycle arrest. This phase of the cell cycle
is known to be the most radiosensitive, with a relative
sensitivity 2.5 times greater than that of G1/S.13 Contributing
to its synergy with radiation, docetaxel is also cytotoxic in the
S phase, the most radioresistant part of the cell cycle.13,14
Recent biologic studies have also revealed an important
function of taxanes in the phosphorylation of antiapoptotic
protein bcl-2.15,16 This may further enhance radiation cyto-
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toxicity by abrogating the immortalizing function of anti-
apoptotic proteins.
Gefitinib is a small molecule tyrosine kinase inhibitor,
which inhibits epidermal growth factor receptor (EGFR)
signaling by blocking the intracellular adenosine triphos-
phate-binding site.17 Blockade of EGFR function improves
the outcomes of patients with metastatic NSCLC. The utility
of these drugs for treating patients with stage III disease has
not been adequately studied. There is preclinical evidence
that demonstrates that EGFR blockade potentiates the antitu-
mor efficacy of radiation.18,19 This mechanism of radiosensi-
tivity is poorly understood. EGFR inhibition may render
tumor cells more susceptible to radiation-induced apoptosis
by inhibiting cell repair from sublethal and lethal radiation
damage. In a proof-of-principle clinical trial, EGFR inhibi-
tion has been shown to decrease cyclin D1 protein expression
and reduce the percentage of lung cancer cells in the radio-
resistant S-phase of the cell cycle by inducing G1 arrest.20 A
recently published phase III trial demonstrated a local control
benefit and an overall survival benefit when the EGFR anti-
body, cetuximab, was combined with radiation therapy in
patients with advanced head and neck cancer.21
At the time when this study was initiated, preclinical
evidence demonstrated the potent radiation sensitizing activity
of docetaxel, and emerging data suggested that EGFR directed
therapies might also potentiate radiation. Therefore, we sought
to define the maximum tolerated dose (MTD) of weekly do-
cetaxel that could be given with daily gefitinib and concurrent
thoracic radiation in a phase I study. The reported MTD for
docetaxel (alone) given with concurrent thoracic radiation is in
the range of 20 mg/m2 and 30 mg/m2, resulting in our rationale
for starting at a dose of 15 mg/m2 in our trial.22–24 It should be
noted that this study, as a secondary end point, did attempt to
discern prospectively, the tumor EGFR and Kras mutation status
before patient enrollment. Because most of patients were diag-
nosed with a fine needle biopsy, the material available for
analysis was most often insufficient.
PATIENTS AND METHODS
Eligibility
Patients with histologically or cytologically documented
stage IIIA/IIIB NSCLC deemed to be unresectable or inoperable
were eligible. Patients with involvement of the scalene, supra-
clavicular, contralateral hilar nodes, cytologically positive pleu-
ral effusions, or patients who had received prior chemotherapy
or radiation therapy for NSCLC were not eligible. Additional
inclusion criteria included patient age 18 years, Eastern Co-
operative Oncology Group Performance Status 0 to 1, adequate
bone marrow function (granulocytes 1500/l, platelets
100,000/l, and hemoglobin 8.0 g/dl), adequate kidney
function (serum creatinine 1.5  upper limit of normal),
adequate liver function (bilirubin 1.5 mg/dl, aspartate ami-
notransferase [serum glutamic oxaloacetic transaminase]
2  upper limit of normal), and adequate lung function
(forced expiratory volume in 1 second 1.2 liters). Patients
were excluded if 2 weeks had elapsed since formal explor-
atory thoracotomy. Treatment with a nonapproved or inves-
tigational drug within 30 days of the initiation of treatment or
prior use of EGFR targeting drugs disqualified patients from
the study. Patients with currently active malignancy other
than nonmelanoma skin cancer were considered ineligible,
with the exception of those that had completed therapy, and
were considered to be less than a 30% risk of relapse per their
physicians.
Any patients with a history of severe hypersensitivity
reaction to docetaxel or other drugs formulated with polysor-
bate 80, and those with known severe hypersensitivity to
gefitinib or any excipients of that product were also excluded.
Patients with evidence of severe or uncontrolled systemic
disease, any other significant clinical disorder, or laboratory
finding determined to be a contraindication to participation in
the trial were excluded. Similarly, criteria for exclusion
extended to any patient demonstrating a  grade 1 neurop-
athy, irrespective of etiology, and any patient with evidence
of clinically active interstitial lung disease. Concomitant use
of phenytoin, carbamazepine, rifampicin, barbiturates, or St.
John’s Wort was also a reason for exclusion from the study.
All patients signed informed consent forms that were
approved by the Institutional Review Board at the Wake
Forest University Baptist Medical Center.
Treatment Schema
The complete 15-week treatment course consisted of a
7-week concurrent chemoradiation phase, followed by a
2-week rest period and subsequent 6-week consolidation
phase. During the chemoradiation phase, patients received
daily (M-F) radiation to a total dose of 70 Gy, oral adminis-
tration of gefitinib at 250 mg/d, and docetaxel 15 to 30 mg/m2
administered once per week IV over 30 minutes. During the
2-week rest period, patients received only the 250 mg of
gefitinib per day. During the consolidation chemotherapy
phase, patients continued gefitinib at 250 mg and received
docetaxel 75 mg/m2 administered IV over 60 minutes every 3
weeks for two cycles. The dose of docetaxel during the
chemoradiation was increased in a stepwise fashion in incre-
ments of 5 mg/m2 from a starting dose of 15 mg/m2 based on
dose-limiting toxicities (DLT) encountered at the previous
dose level. Three patients in a dose cohort had to have
completed the complete course of chemoradiation therapy
before escalation to the next dose level. Intrapatient dose
escalation was not permitted. If two of the three patients in a
cohort experienced DLT, it was determined that the MTD had
been exceeded, and the preceding dose level was declared the
MTD. If one patient of the initial three experienced DLT,
then the dose level was expanded to a minimum of six
patients. If two or more of these six patients experienced
DLT, it was determined that the MTD was exceeded, and the
preceding dose level was declared the MTD.
DLT was defined as any of the following: grade 4
neutropenia, grade 3 thrombocytopenia, and grade 3
nonhematologic toxicity that resulted in a 7 day interrup-
tion of therapy. The Common Terminology Criteria for Ad-
verse Events, version 3.0, of the NCI were used.
Radiation Guidelines
All patients were treated with 3D conformal treatment
planning. The specific design and configuration of the fields
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were individualized based on the volume and location of the
disease. Treatment volumes were based on preoperative com-
puted tomography scans of the thorax. The gross tumor
volume (GTV) consisted of the primary tumor and any
involved lymph nodes as determined by radiologic criteria of
1.0 cm short axis, central necrosis, or positron emission
tomography positivity. Clinical target volume 1 (CTV1) in-
cluded the GTV plus 1.0 cm margin, with the exception of the
interface of the primary lesion and normal pulmonary paren-
chyma, where it was a minimum of 0.5 cm. Elective treat-
ment of next echelon lymph nodes was permitted for inclu-
sion in CTV1. CTV2 included only the GTV plus a 1.0 cm
margin, except at the interface of the lesion and pulmonary
parenchyma where it was 0.5 cm. Planning target volumes 1
and 2 (PTV1 and PTV2) were 1.0 cm expansions on the
CTV1 and CTV2, respectively. PTV1 received 40 Gy in 2 Gy
daily fractions4 weeks, subsequently PTV2 received 30 Gy
in 2 Gy daily fractions for 3 weeks. In all instances, the entire
PTV was encompassed within the 95% isodose surface and
no more than 10% of the volume within this isodose surface
receiving greater than 110% of the prescription dose as
evaluated by dose volume histogram. Although the maximum
point dose for the spinal cord could not exceed 49 Gy, there
were no V20 (percent lung allowed to receive 20 Gy in the
composite radiation portals) dose constraint requirements.
The total lung volume was defined as the volume of both
lungs (combined pair organ) minus the GTV.
Chemotherapy Guidelines
During concurrent chemoradiation, the docetaxel dose
was reduced by 50% if the granulocyte count was 500 to
999/l or platelet count was 50,000 to 74,999/l on the day
of planned treatment. Treatment was omitted for granulocyte
count 500/l or platelet count 50,000/l. The radiation
was continued if the docetaxel was held; however, if a
cessation of radiation therapy was warranted, then both ge-
fitinib and docetaxel were held for the remainder of the
concurrent phase of the treatment.
During the consolidation phase, if the granulocyte
count was 1500/l or the platelet count was 100,000/l
on the scheduled day of administration, therapy was delayed
for 1 week for count recovery. The docetaxel dose was
reduced by 25% in subsequent cycles for a granulocyte nadir
count 500/l or a platelet nadir count 25,000/l for 7
days or more or for febrile neutropenia (defined as ANC
500 and two measurements of T 38.2°C [100.8°F]).
Throughout the study, patients received gefitinib at a
dose of 250 mg PO daily until disease progression or study
closure.
Statistical Considerations
The statistical analysis was performed at the Wake Forest
University Comprehensive Cancer Center. The frequency and
severity of all side effects and toxicities were tabulated and
analyzed using categorical techniques. Although understanding
the limitations of a phase I trial, Kaplan-Meier methods were
used to estimate the time to progression and survival distribu-
tions, and response was determined using the RECIST.25
RESULTS
Patient Characteristics
Between December 3, 2003, and April 24, 2007, 16
eligible patients were enrolled. One patient received do-
cetaxel at a lower dose level than outlined in the study and
was deemed not evaluable for toxicity. Another patient had
no repeat computed tomography and was therefore not evalu-
able for response. The pretreatment characteristics of the
patients are listed in Table 1. The median age was 63.6 years
(range 43–79 years), and all except one patient had a perfor-
mance status of 1.
Toxicity
Tables 2 and 3 summarize the grade 3 to 5 treatment-
related toxicities observed during the combined modality part
of the study. At our starting dose of 15 mg/m2, grade IV
neutropenia and grade III pulmonary toxicities were observed
in the same patient, allowing us to continue our dose escala-
tion. Although there were no 7-day interruptions in treat-
ment during the chemoradiation, two patients were unable to
complete the planned 70 Gy, stopping at 62 Gy and 66 Gy,
respectively, for toxicity. Two patients missed the week 4
dose of concurrent chemotherapy, whereas two additional
patients missed the week 5 and week 7 dosing, respectively,
for toxicity. Unacceptable DLT were encountered at the 25
mg/m2 docetaxel dose level. Of the four patients entered at
the 25 mg/m2 dose level, one experienced a fatal radiation-
related pneumonitis, the second experienced an uneventful
grade 3 diarrhea, whereas the third patient had grade 3
esophagitis that resulted in a greater than 7-day hospital
admission. This same patient at the 25 mg/m2 dose level also
experienced a grade 4 neutropenia.
Two patients suffered fatal pulmonary toxicities that
were at least possibly due to treatment. As described above,
a patient at the 25 mg/m2 experienced what clinically and
radiographically appeared to be a radiation-related pneumo-
nitis. The second patient at the 20 mg/m2 dose level devel-
oped grade 4 hypoxia that ultimately progressed to a grade 5
event. The review of the radiologic studies suggested that this
was a bilateral, diffuse interstitial process most consistent
with the known pulmonary toxicity described for gefitinib.
The third fatal pulmonary event was observed, but after a
careful clinical and radiographic review by independent phy-
TABLE 1. Patient Characteristics
N 16







Performance status, N (%)
0 1 (6)
1 15 (94)
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sicians, this was deemed to have been the result of an
unrelated pulmonary infection. Overall, grade 3 to 5 pulmo-
nary toxicities were observed in 20% of patients—the pul-
monary and V20 parameters are outlined in Figure 1.
In general, the hematologic toxicity was modest, with
grade 3 to 4 events observed in 27% of patients. Two patients
experienced grade 4 neutropenia: one patient at the 15 mg/m2
dose level and the other at the 25 mg/m2 dose level, respectively.
Survival
Although the primary end point of this study was to
determine the docetaxel MTD when given with current tho-
racic radiation and gefitinib chemotherapy, best response to
therapy is shown in Table 4. The overall median survival for
all patients was 21.0 months (95% confidence interval 5.1—
not reached). The median progression-free survival was 7.1
months (95% CI: 5.1–10.8).
DISCUSSION
At the time this phase I trial was initiated, the preclin-
ical rationale for this treatment strategy was compelling, and
the results from the SWOG S002326 trial of maintenance
gefitinib and the HOG27 consolidation docetaxel trial were
unavailable. Although this study did attempt, unsuccessfully,
to discern the EGFR/Kras mutation status in all tumors
treated, the emerging clinical studies of patients with specific
genetic mutations benefiting when treated with EGFR ty-
rosine kinase inhibitor were also unavailable.
The results from other phase I/II trials, which have
incorporated concurrent EGFR inhibition with chemoradia-
tion, have demonstrated similar results to those seen in this
study.11,28,29 Unfortunately, these additional trials of chemo-
radiation with gefitinib did not prospectively select patients
based on the tumor EGFR or Kras mutation status. In this
trial, we have determined that the MTD in unselected patients
receiving weekly docetaxel when given concurrent with 70
Gy conformal thoracic radiation and daily gefitinib is 20
mg/m2. The DLTs seem related to the potent radiosensitizing
effects of this combination. Although hematologic toxicities
were not uncommon, they were manageable and self-limiting.
The most frequent and significant toxicities were pulmonary
and esophageal.
Other investigators who have attempted to incorporate
EGFR tyrosine kinase inhibitors into conventional chemora-
diation regimens have also reported moderate toxicity. In a
study reported by Stinchcombe et al.,11 23 unselected patients
received induction carboplatin, paclitaxel, and irinotecan,
followed by 74 Gy thoracic radiation with concurrent ge-
fitinib, carboplatin, and paclitaxel, and then maintenance
gefitinib. Grade 3 esophagitis was significant and observed in
20% of patients. The authors also report a median progression
free survival of 9 months and a median overall survival of 16
months, which is comparable to our findings. In a second
study from Choong et al.,28 34 patients were randomized to
two different conventional platinum-based chemoradiation ther-
apies with the addition of concurrent daily erlotinib. Grade 3
esophagitis was observed in 26% of patients and a median
survival of 10 months and 14 months for the two respective
cohorts was observed. Although the investigators assessed tu-
FIGURE 1. Patients experiencing an acute  grade III radia-
tion pneumonitis are represented by the open circles. FEV-1,
forced expiratory volume in 1 second. Pneumonitis was de-
fined by National Cancer Institute CTC version 3.0. V20
reflects percent lung receiving 20 Gy.













3 4 5 3 4 5 3 4 5 3 4 5
15 0 1 0 0 0 0 0 0 0 1 0 0
20 1 0 0 0 0 0 1 0 0 0 0 0
25 0 1 0 0 0 0 0 0 0 1 0 0
a Represents the highest grade toxicity experienced by a patient within each
category/column.










3 4 5 3 4 5 3 4 5
15 1 0 0 0 0 0 0 0 0
20 0 0 1 1 0 0 0 0 0
25 0 0 1 2 0 0 1 0 0
a Represents the highest grade toxicity experienced by a patient within each
category/column.















15 6 0 2 3 0 1
20 6 1a 0 2 3 0
25 4 0 0 1 2 1
a The predefined imaging to assess response was not performed.
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mors for EGFR status by immunohistochemistry or fluorescence
in situ hybridization post hoc, patients with EGFR positive
tumors showed no significant overall survival benefit.
The Cancer and Leukemia Group B (CALGB) has
reported phase II results with induction paclitaxel and carbo-
platin followed by either 66 Gy thoracic radiation with
gefitinib in the defined “poor risk” patients or 66 Gy thoracic
radiation with gefitinib, carboplatin, and paclitaxel in the
defined “good risk” patients.29 In both arms, maintenance
gefitinib was continued after chemoradiation. Interestingly,
the “poor risk” patients who received only gefitinib concur-
rent with radiation performed better with a median progres-
sion-free survival of 11.5 months and a median overall
survival of 19 months compared with the “good risk” patients
who received both chemotherapy and gefitinib concurrently
with thoracic radiation and had a median progression-free sur-
vival of 9.2 months and a median overall survival of 12 months.
EGFR gene amplification, EGFR mutation, and K-ras status
were not accounted for in the CALGB study. Although
differences in treatement-related toxicities were observed, it
is possible that imbalances in tumor molecular profiles con-
tributed to differences in outcome.30
The interaction of EGFR inhibitors with radiation sen-
sitizing chemotherapy may be antagonistic. This concept is
supported by preclinical data, which have investigated the
sequence dependence of cytotoxic chemotherapy and EGFR
inhibitors.31–33 Several clinical studies in patients with met-
astatic NSCLC have demonstrated a lack of benefit when
chemotherapy is combined with gefitinib or erlotinib.34–36
The recently reported Iressa Pan-Asia Study demonstrated
that for select patient populations, EGFR inhibitors alone
may perform as well as combination chemotherapy.37 Given
this result and the results of the CALGB study discussed
above, a phase II trial investigating induction chemotherapy
followed by concurrent erlotinib (alone) and radiation is
currently enrolling.
CONCLUSIONS
Concurrent thoracic radiation with weekly docetaxel
and daily gefitinib is feasible with moderate toxicity. The
MTD of docetaxel is 20 mg/m2 when combined with 70 Gy
thoracic radiation and gefitinib 250 mg daily.
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